{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:06:57Z","timestamp":1791245217922,"version":"4.1.0"},"reference-count":10,"publisher":"American Association for Cancer Research (AACR)","issue":"5","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007911","name":"University of California, San Diego","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007911","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Hypogammaglobulinemia is common in patients with chronic lymphocytic leukemia (CLL). Prior studies demonstrated that intravenous immunoglobulin (IVIG) reduced infections without survival benefit. We conducted a single-institution retrospective cohort study of infectious outcomes in patients with CLL who received IVIG between 2005 and 2022 to assess the impact of IVIG across evolving CLL treatment paradigms, including the introduction of targeted agents. Fifty-two patients met the inclusion criteria of IVIG use for hypogammaglobulinemia and recurrent infections, with also any infection up to 1 year prior to the initiation of IVIG. Baseline mean IgG prior to IVIG was 389 mg\/dL (range, 93\u2013891 mg\/dL). By design, all 52 patients (100%) experienced at least one CTCAE grade \u22652 infection in the 12 months prior to IVIG initiation. In the 12 months following IVIG initiation, only 17 patients (33%) experienced a grade \u22652 infection. IVIG therapy was associated with a 67% reduction in risk of grade 2 infections (RR 0.33; 95% confidence interval, 0.22\u20130.48; P &amp;lt; 0.0001), corresponding to an absolute risk reduction of 67% and a number needed to treat of 1.5. The mean number of infections per patient also reduced from 2.1 to 0.4. Baseline IgA and IgG levels, as well as recent CLL treatment, were not predictors of residual post-IVIG infections. These findings suggest that IVIG may yield meaningful improvements in patient quality of life by reducing infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Hypogammaglobulinemia and recurrent infections remain a complication of CLL, despite contemporary agents. In this 2005 to 2022 retrospective cohort, IVIG initiation was associated with a large reduction in CTCAE grade \u22652 infections: only 33% of patients had a post-IVIG grade \u22652 infection versus all patients before IVIG. Residual infections were not explained by baseline IgG\/IgA levels or recent therapy. IVIG may be an effective supportive-care strategy in patients with CLL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0177","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T21:02:37Z","timestamp":1778101357000},"page":"1146-1150","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intravenous Immunoglobulin Reduces Infections for Patients with Chronic Lymphocytic Leukemia: A Single-Center Retrospective Analysis"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9511-1955","authenticated-orcid":false,"given":"Nirja N.","family":"Shah","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0168r3w48","id-type":"ROR","asserted-by":"publisher"}],"name":"UC San Diego 1 Department of Medicine, , La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2020-0638","authenticated-orcid":false,"given":"Tulsi","family":"Patel","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0168r3w48","id-type":"ROR","asserted-by":"publisher"}],"name":"UC San Diego 1 Department of Medicine, , La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0064-4549","authenticated-orcid":false,"given":"Thomas J.","family":"Kipps","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0168r3w48","id-type":"ROR","asserted-by":"publisher"}],"name":"UC San Diego 1 Department of Medicine, , La Jolla, California."},{"id":[{"id":"https:\/\/ror.org\/0168r3w48","id-type":"ROR","asserted-by":"publisher"}],"name":"UC San Diego 2 Division of Hematology and Cellular Therapy, Department of Medicine, , La Jolla, California."},{"name":"3Center for Novel Therapeutics, La Jolla, California."},{"name":"4UC San Diego Sanford Stem Cell Institute, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9107-2186","authenticated-orcid":false,"given":"Michael Y.","family":"Choi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0168r3w48","id-type":"ROR","asserted-by":"publisher"}],"name":"UC San Diego 1 Department of Medicine, , La Jolla, California."},{"id":[{"id":"https:\/\/ror.org\/0168r3w48","id-type":"ROR","asserted-by":"publisher"}],"name":"UC San Diego 2 Division of Hematology and Cellular Therapy, Department of Medicine, , La Jolla, California."},{"name":"3Center for Novel Therapeutics, La Jolla, California."},{"name":"4UC San Diego Sanford Stem Cell Institute, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"2026051803345417500_bib1","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1182\/blood.V126.23.1740.1740","article-title":"Improved survival for patients with CLL in the era of combination chemoimmunotherapy - a Danish population based study","volume":"126","author":"da Cunha-Bang","year":"2015","journal-title":"Blood"},{"key":"2026051803345417500_bib2","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.3324\/haematol.2017.182006","article-title":"Incidence and predictors of infection among patients prior to treatment of chronic lymphocytic leukemia: a Danish nationwide cohort study","volume":"103","author":"Andersen","year":"2018","journal-title":"Haematologica"},{"key":"2026051803345417500_bib3","doi-asserted-by":"crossref","first-page":"1062376","DOI":"10.3389\/fimmu.2023.1062376","article-title":"Should treatment of hypogammaglobulinemia with immunoglobulin replacement therapy (IGRT) become standard of care in patients with chronic lymphocytic leukemia?","volume":"14","author":"Noto","year":"2023","journal-title":"Front Immunol"},{"key":"2026051803345417500_bib4","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a work group report of the AAAAI primary immunodeficiency and altered immune response committees","volume":"149","author":"Otani","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2026051803345417500_bib5","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1056\/NEJM198810063191403","article-title":"Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial","volume":"319","author":"Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia","year":"1988","journal-title":"N Engl J Med"},{"key":"2026051803345417500_bib6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2257.1995.tb00322.x","article-title":"Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia","volume":"17","author":"Boughton","year":"1995","journal-title":"Clin Lab Haematol"},{"key":"2026051803345417500_bib7","first-page":"CD006501","article-title":"Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation","volume":"2008","author":"Raanani","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"2026051803345417500_bib8","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2015-04-639203","article-title":"Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"key":"2026051803345417500_bib9","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1182\/bloodadvances.2025015867","article-title":"Immunoglobulin use, survival, and infection outcomes in patients with chronic lymphocytic leukemia","volume":"9","author":"Carrillo de Albornoz","year":"2025","journal-title":"Blood Adv"},{"key":"2026051803345417500_bib10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1056\/NEJM199107113250202","article-title":"Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia","volume":"325","author":"Weeks","year":"1991","journal-title":"N Engl J Med"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0177\/3792828\/crc-26-0177.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/5\/1146\/3794684\/crc-26-0177.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/5\/1146\/3794684\/crc-26-0177.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T07:35:01Z","timestamp":1779089701000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/5\/1146\/785266\/Intravenous-Immunoglobulin-Reduces-Infections-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0177","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.32697607","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32697610","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8541916","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}